In the US this week, supplier of botanical extracts for the
pharmaceutical industry Pharmachem Laboratories announced that it
has acquired 'the largest botanical extraction facility in North
America, producing extracts for the...
An EU funded project is building the critical mass of knowledge
required to ensure that Europe meets the Lisbon objective of
becoming the world's most competitive knowledge-based economy by
2010, reports Cordis.
The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...
The European Commission has proposed new regulations allowing
Member States to grant aid for research and development (R&D)
to small and medium sized enterprises (SMEs), without having to
first apply for clearance from the Commission,...
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US manufacturer of vitamins, minerals, herbs and supplements
D&E Pharmaceuticals, has launched a contract manufacturing
services initiative, principally aimed at small to medium sized
US zuChem, a development-stage company that focuses on
commercialising manufacturing processes for glycochemicals, has
raised a considerable chunk of capital. Funds earmarked for
development of new sugar-based pharmaceutical intermediates.
BioInnovators, a USA-based consultancy serving the pharmaceutical
and biotech industries, has developed a new set of tools designed
to help pharmaceutical and dietary supplement companies understand
and improve cost and time efficiencies...
In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.
BioProgress, a UK company specialising in the manufacture of
non-gelatin capsules, looks set to become only the second UK
biopharmaceutical company to brave the equity markets this year
with a transfer of its listing Nasdaq's...